LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Lista de Ações・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Fechado

1.62 -8.47

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.6099999999999999

Máximo

1.6400000000000001

Indicadores-chave
By Trading Economics
Rendimento	-23T -3.5M
EPS	-0.06
Funcionários	7
EBITDA	2.4M -3.5M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+237.42% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.4M 100M
Abertura anterior	10.09
Fecho anterior	1.62

Aldeyra Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de mar. de 2026, 13:34 UTC

Grandes Movimentos do Mercado

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

16 de dez. de 2025, 11:43 UTC

Grandes Movimentos do Mercado

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

Comparação entre Pares

Variação de preço

Aldeyra Therapeutics Inc Previsão

Preço-alvo

By TipRanks

237.42% parte superior

Previsão para 12 meses

Média 5.5 USD 237.42%

Máximo 9 USD

Mínimo 2 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Aldeyra Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Aldeyra Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.